CompletedPhase 1NCT03792516
Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)
Studying Vulvar intraepithelial neoplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Principal Investigator
- Cornelia L Trimble, MDJohns Hopkins University
- Intervention
- artesunate ointment 40%(drug)
- Enrollment
- 15 target
- Eligibility
- 18-100 years · FEMALE
- Timeline
- 2019 – 2024
Study locations (4)
- Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
- Cleveland Clinic Fairview Hospital, Cleveland, Ohio, United States
- Cleveland Clinic Foundation - Main Campus, Cleveland, Ohio, United States
- Cleveland Clinic - Hillcrest Hospital, Mayfield Heights, Ohio, United States
Collaborators
Frantz Viral Therapeutics, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03792516 on ClinicalTrials.gov